8-K current report · filed Oct 14, 2026

ImmunityBio, Inc. (IBRX) 8-K Current Report: October 14, 2026

Item EX-99.1Item 7.01IBRX overview

Short answer

ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on October 14, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). FDA expanded ANKTIVA plus BCG approval to BCG-unresponsive NMIBC with papillary-only tumors.

ImmunityBio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA expanded ANKTIVA plus BCG approval to BCG-unresponsive NMIBC with papillary-only tumors
  • Broader eligible patient population, supporting potential commercial uptake of ANKTIVA
  • Press release dated October 14, 2026, contains the full announcement details

Item EX-99.1 · Exhibit EX-99.1

  • FDA expanded ANKTIVA plus BCG approval to all BCG-unresponsive NMIBC, including papillary-only tumors
  • Papillary disease represents approximately 85% of the NMIBC patient population, materially broadening ANKTIVA’s addressable market
  • First FDA-approved therapy covering both CIS and papillary-only BCG-unresponsive NMIBC, strengthening competitive positioning
  • QUILT-3.032 Cohort A: 62% complete response among 77 patients, with 58% maintaining response at least 12 months
  • Commercial upside depends on physician adoption, reimbursement, supply capacity, and safe use given cystectomy-delay warning

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ImmunityBio, Inc. 8-K filings

Get the next IBRX 8-K as it lands

Follow IBRX for push alerts, or ask the research agent what this filing means.